In San Francisco, a new company focused on using artificial intelligence to advance drug discovery has launched with more than $1 billion in capital.
The company, named Xaira Therapeutics, has a mission to “redesign the way medicines are discovered and developed through the end-to-end application of emerging AI technologies.”
The company will be led by Marc Tessier Lavigne, former chief scientific officer of the Roche (ROG: SIX) subsidiary.
This article can only be viewed by registered users. Register for free to read more. Your free trial gives you access to his week of exclusive features, interviews, recaps, and commentary from some of the sharpest minds in pharma and biotech. If you are already a registered user, please log in. If your trial is over, you can subscribe here.
TRY BEFORE YOU BUY
• All the news that moves the pharmaceutical and biotech needle.
• Exclusive features, podcasts, interviews, data analysis and commentary from a global network of life science reporters.
• Receive The Pharma Letter's daily news bulletins, free forever.
become a subscriber
• Free access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, financing, regulation, patents and legislation, executive appointments, commercial strategy, and financial results.
• Daily roundup of major events in pharma and biotechnology.
• Host monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.
